Clinical trials
Glioma trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Recruiting | 10 |
| Active, not recruiting | 7 |
| Terminated | 6 |
| Not yet recruiting | 4 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 5 |
| Novartis Pharmaceuticals | 5 |
| Clinica Universidad de Navarra, Universidad de Navarra | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Hoffmann-La Roche | 2 |
| Hospital del Rio Hortega | 2 |
| Juan M Garcia-Gomez | 2 |
| Actuate Therapeutics Inc. | 1 |
| Amgen | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glioma | 47 |
| Glioblastoma | 20 |
| Brain Neoplasms | 9 |
| Astrocytoma | 7 |
| Ependymoma | 6 |
| Medulloblastoma | 6 |
| Central Nervous System Neoplasms | 5 |
| Neoplasms | 5 |
| Neuroblastoma | 5 |
| Oligodendroglioma | 5 |
Trials
Showing 26 to 47 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.